Alectinib is a molecule from the second generation, which has proved antitumor effect on NSCLC patients with ALK rearrangement who have benefited previously from crizotinib which was approved in December 2015 and subsequently in November 2017 was indicated as first-line setting of patients with advanced ALK-positive NSCLC [92]. Here, ALK is linked to non-small cell lung carcinoma.